基础医学与临床 ›› 2018, Vol. 38 ›› Issue (2): 153-157.

• 研究论文 • 上一篇    下一篇

中国134例黑色素瘤患者P16INK4a、CDK4和CCND1基因突变及其临床意义

吴晓雯,闫君雅,代杰,孔燕,郭军   

  1. 北京肿瘤医院
  • 收稿日期:2017-02-23 修回日期:2017-04-26 出版日期:2018-02-05 发布日期:2018-01-24
  • 通讯作者: 郭军 E-mail:guoj307@126.com
  • 基金资助:
    国家自然科学基金;国家自然科学基金;北京市自然科学基金;北京市自然科学基金;北京市百千万人才工程

Mutations of P16INK4a/CDK4/CCND1 genes in 134 Chinese melanoma patients and their clinical significance

  • Received:2017-02-23 Revised:2017-04-26 Online:2018-02-05 Published:2018-01-24

摘要: 目的 通过分析中国黑色素瘤患者P16INK4a、CDK4和CCND1基因的突变情况,探索其可能的临床意义。方法 研究共纳入2010年1月至2014年12月在北京肿瘤医院就诊的134例中国黑色素瘤患者,收集其肿瘤组织切片(肢端型37例,黏膜型87例,非肢端皮肤型10例),通过PCR扩增及Sanger测序,检测P16INK4a、CDK4和CCND1基因突变情况,并分析基因突变情况与临床预后的相关性。结果 134例黑色素瘤患者P16INK4a、CDK4和CCND1基因突变率分别为8.2% (11/134) 、0.75%(1/134)和0%(0/134)。81.8%(9/11) 的P16INK4a基因突变可能影响蛋白质功能。P16INK4a野生型患者的总生存期明显长于突变型患者(c2= 8.872,P<0.01)。P16INK4a基因突变是影响黑色素瘤的独立预后因素(P<0.05)。结论 P16INK4a基因可能成为黑色素瘤靶向治疗新的突破点。

关键词: 黑色素瘤, P16INK4a, CDK4, CCND1, 基因突变

Abstract: Objective To investigate the frequency of P16INK4a, CDK4 and CCND1 gene mutations in Chinese melanoma patients and find out the possible clinical significance. Methods The samples in this study were from 134 melanoma patients(37 acral melanomas,87 mucosal melanomas,10 non-acral skin melanomas), hospitalized in Beijing Cancer Hospital from January 2010 to December 2014.The mutation status of P16INK4a,CDK4 and CCND1 was detected by PCR amplification and Sanger sequence.Statistical analyses were used to investigate the correlation between gene mutation and prognosis. Results Among the 134 samples, the mutation frequency of P16INK4a, CDK4, CCND1 was 8.2%(11/134), 0.75 %(1/134) ,0 %(0/134) respectively.81.8% (9/11) of the P16INK4a gene mutation may affect protein function.The median survival time of melanoma patients with P16INK4a mutations was significantly shorter than the patients without P16INK4a mutations (c2= 8.872,P<0.01).P16INK4a gene mutation is an independent prognostic factor for melanoma (P <0.05). Conclusions P16INK4a may be a breaking point of targeted therapy for melanoma.

Key words: Melanoma, P16INK4a, CDK4, CCND1, Gene mutation

中图分类号: